Steven M. Fruchtman - Aug 2, 2022 Form 4 Insider Report for Onconova Therapeutics, Inc. (ONTX)

Role: PRESIDENT, CHIEF EXECUTIVE OFF, Director
Signature: /s/ Mark Guerin, Attorney-in-Fact
Stock symbol: ONTX
Transactions as of: Aug 2, 2022
Transactions value $: -$6,022
Form type: 4
Date filed: 8/4/2022, 04:30 PM
Previous filing: Feb 9, 2022
Next filing: Feb 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ONTX	Common Stock	Options Exercise		+12.6K	+69.31%		30.7K	Aug 2, 2022	Direct	F1
transaction	ONTX	Common Stock	Tax liability	-$6.02K	-4.56K	-14.86%	$1.32	26.1K	Aug 3, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ONTX	Restricted Stock Units	Options Exercise	$0	-12.6K	-33.33%	$0.00	25.1K	Aug 2, 2022	Common Stock	12.6K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	On August 2, 2021 the reporting person was granted 37,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.